Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Tofacitinib Citrate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 16,069Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 540737-29-9, Tasocitinib citrate, Xeljanz, Cp-690550 citrate, Tofacitinib (citrate), Tofacitinib (cp-690550) citrate
    Molecular Formula
    C22H28N6O8
    Molecular Weight
    504.5  g/mol
    InChI Key
    SYIKUFDOYJFGBQ-YLAFAASESA-N
    FDA UNII
    O1FF4DIV0D
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    2-hydroxypropane-1,2,3-tricarboxylic acid;3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile
    2.1.2 InChI
    InChI=1S/C16H20N6O.C6H8O7/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16;7-3(8)1-6(13,5(11)12)2-4(9)10/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t11-,13+;/m1./s1
    2.1.3 InChI Key
    SYIKUFDOYJFGBQ-YLAFAASESA-N
    2.1.4 Canonical SMILES
    CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
    2.1.5 Isomeric SMILES
    C[C@@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
    2.2 Other Identifiers
    2.2.1 UNII
    O1FF4DIV0D
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Cp 690,550

    2. Cp 690550

    3. Cp-690,550

    4. Cp-690550

    5. Cp690550

    6. Tasocitinib

    7. Tofacitinib

    8. Xeljanz

    2.3.2 Depositor-Supplied Synonyms

    1. 540737-29-9

    2. Tasocitinib Citrate

    3. Xeljanz

    4. Cp-690550 Citrate

    5. Tofacitinib (citrate)

    6. Tofacitinib (cp-690550) Citrate

    7. Xeljanz Xr

    8. Tofacitinib Citrate [usan]

    9. Cp-690,550-10

    10. Tasocitinib Monocitrate

    11. 540737-29-9 (citrate)

    12. Cp-690550-10

    13. Cp 690550 Citrate

    14. O1ff4div0d

    15. 3-((3r,4r)-4-methyl-3-(methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile 2-hydroxypropane-1,2,3-tricarboxylate

    16. Chebi:71197

    17. 1-piperidinepropanenitrile, 4-methyl-3-(methyl-7h-pyrrolo(2,3-d)pyrimidin-4-ylamino)- Beta-oxo-, (3r,4r)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)

    18. 2-hydroxypropane-1,2,3-tricarboxylic Acid; 3-[(3r,4r)-4-methyl-3-[methyl({7h-pyrrolo[2,3-d]pyrimidin-4-yl})amino]piperidin-1-yl]-3-oxopropanenitrile

    19. 2-hydroxypropane-1,2,3-tricarboxylic Acid;3-[(3r,4r)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile

    20. Unii-o1ff4div0d

    21. Mfcd11616529

    22. 3-{(3r,4r)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile 2-hydroxypropane-1,2,3-tricarboxylate

    23. 3-{(3r,4r)-4-methyl-3-[methyl-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile Citrate Salt

    24. 3-{(3r,4r)-4-methyl-3-[methyl-(7h-pyrrolo[2,3-d]pyrimidin-4-yl}-amino]-piperidin-1-yl)-3-oxo-propionitrile Citrate Salt

    25. Xeljanz (tn)

    26. Tofacitinib Monocitrate

    27. Tasocitinib Citric Acid Salt

    28. Cep-18770(delanzomib)

    29. Mls006010058

    30. Schembl1374185

    31. Chembl2103743

    32. Tofacitinib Citrate (jan/usan)

    33. Amy4175

    34. Dtxsid80202404

    35. Ex-a204

    36. Tofacitinib Citrate [jan]

    37. C16h20n6o.c6h8o7

    38. Tofacitinib Monocitrate [mi]

    39. Hy-40354a

    40. S5001

    41. Tofacitinib Citrate [who-dd]

    42. Akos022178222

    43. Cp-690550 - Tofacitinib Citrate

    44. Tofacitinib Citrate, >=98% (hplc)

    45. Ccg-269730

    46. Cs-0928

    47. Tofacitinib Citrate [orange Book]

    48. Ac-25004

    49. As-19392

    50. Bt163661

    51. Smr004701220

    52. Cp-690550 Citrate (tofacitinib Citrate)

    53. Tofacitinib Citrate (cp-690550 Citrate)

    54. Cp 690550-10

    55. D09783

    56. Q27139435

    57. (3r,4r)-4-methyl-3-(methyl-7h-pyrro Lo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepro Panenitrile Citrate

    58. (3r,4r)-4-methyl-3-(methyl-7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)-?-oxo-1-piperidinepropanenitrile Citrate

    59. (3r,4r)-4-methyl-3-(methyl-7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidine Propanenitrile 2-hydroxy-1,2,3-propanetricarboxylate

    60. (3r,4r)-4-methyl-3-(methyl-7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)-ss-oxo-1-piperidinepropanenitrile Citrate Salt

    61. 1-piperidinepropanenitrile, 4-methyl-3-(methyl-7h-pyrrolo(2,3-d)pyrimidin-4-ylamino)-.beta.-oxo-, (3r,4r)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)

    62. 1-piperidinepropanenitrile,4-methyl-3-(methyl-7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-,(3r,4r)-,2-hydroxy-1,2,3-propanetricarboxylate(1:1)

    63. 3-((3r,4r)-4-methyl-3-(methyl(7h-pyrrolo(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxo-propanenitrile2-hydroxypropane-1,2,3-tricarboxylate (1:1)

    64. 3-((3r,4r)-4-methyl-3-(methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile Mono Citrate Salt

    65. 3-{(3r,4r)-4-methyl-3-[methyl-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile Mono Citrate Salt

    2.4 Create Date
    2006-10-25
    3 Chemical and Physical Properties
    Molecular Weight 504.5 g/mol
    Molecular Formula C22H28N6O8
    Hydrogen Bond Donor Count5
    Hydrogen Bond Acceptor Count12
    Rotatable Bond Count8
    Exact Mass504.19686187 g/mol
    Monoisotopic Mass504.19686187 g/mol
    Topological Polar Surface Area221 Ų
    Heavy Atom Count36
    Formal Charge0
    Complexity716
    Isotope Atom Count0
    Defined Atom Stereocenter Count2
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 2  
    Drug NameXeljanz
    PubMed HealthTofacitinib (By mouth)
    Drug ClassesAntirheumatic, Musculoskeletal Agent
    Drug LabelXELJANZ is the citrate salt of tofacitinib, a JAK inhibitor.Tofacitinib citrate is a white to off-white powder with the following chemical name: (3R,4R)-4-methyl-3-(methyl-7H-pyrrolo [2,3-d]pyrimidin-4-ylamino)--oxo-1-piperidinepropanenitrile, 2-hy...
    Active IngredientTofacitinib citrate
    Dosage FormTablet
    RouteOral
    Strengtheq 5mg base
    Market StatusPrescription
    CompanyPf Prism Cv

    2 of 2  
    Drug NameXeljanz
    PubMed HealthTofacitinib (By mouth)
    Drug ClassesAntirheumatic, Musculoskeletal Agent
    Drug LabelXELJANZ is the citrate salt of tofacitinib, a JAK inhibitor.Tofacitinib citrate is a white to off-white powder with the following chemical name: (3R,4R)-4-methyl-3-(methyl-7H-pyrrolo [2,3-d]pyrimidin-4-ylamino)--oxo-1-piperidinepropanenitrile, 2-hy...
    Active IngredientTofacitinib citrate
    Dosage FormTablet
    RouteOral
    Strengtheq 5mg base
    Market StatusPrescription
    CompanyPf Prism Cv

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Janus Kinase Inhibitors

    Agents that inhibit JANUS KINASES. (See all compounds classified as Janus Kinase Inhibitors.)